A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Lymphoma|Non-Hodgkin Lymphoma|Hodgkin Lymphoma
DRUG: VI-0609|DRUG: BiCNU
Evaluation of infusion-related toxicities, Within 24 hours post infusion|Evaluation of unacceptable toxicities, From start of BEAM through Day 30 post-AHCT
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.